Atsushi Tanaka

Medizinische Hochschule Hannover — Germany

Medicine · Health Sciences

53h-index10.3kcitations343works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Diseases and Immunity(189), Liver Disease Diagnosis and Treatment(144), Pediatric Hepatobiliary Diseases and Treatments(91), Gallbladder and Bile Duct Disorders(48), Liver Disease and Transplantation(38)

Publications336 total

Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025
Hepatology International·2025· 1 cited
Optimizing clinic consultations in primary biliary cholangitis: International consensus recommendations
Hepatology Communications·2025Open Access
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
˜The œLancet. Gastroenterology & hepatology·2025· 3 cited
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
˜The œLancet. Gastroenterology & hepatology·2025· 1 cited
Histological characteristics of primary biliary cholangitis in patients with incomplete responses to ursodeoxycholic acid
Human Pathology·2025Open Access
Bezafibrate for primary biliary cholangitis: time to act on the evidence
Nature Reviews Gastroenterology & Hepatology·2025· 2 cited
Liver Volumetry Enhances Prediction of Acute Pancreatitis in Acute Liver Failure: A Nationwide Registry Study
Hepatology Research·2025
Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial
Hepatology Communications·2025Open Access
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis
Journal of Hepatology·2025· 2 citedOpen Access
O8 Linerixibat significantly improves cholestatic pruritus in primary biliary cholangitis (PBC): results of the pivotal phase 3 GLISTEN trial
2025· 1 cited
Clinical Characteristics and Long‐Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd‐Generation Nationwide Survey
Hepatology Research·2025· 1 citedOpen Access
A Guide for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Induced Liver Injury
Kanzo·2025Open Access
GS-011 Linerixibat significantly improves cholestatic pruritus in primary biliary cholangitis: results of the pivotal phase 3 GLISTEN trial
Journal of Hepatology·2025· 5 cited
Mo1566: CLINICOPATHOLOGICAL AND IMAGING FEATURES OF IMMUNE CHECKPOINT INHIBITOR-RELATED CHOLANGITIS: A NATIONWIDE MULTICENTER RETROSPECTIVE STUDY IN JAPAN.
Gastroenterology·2025
THU-324 Does steatotic liver disease influence treatment response and clinical outcomes in primary biliary cholangitis?
Journal of Hepatology·2025
OS-088 FiOCA study: comparative analysis of transplant-free survival in primary biliary cholangitis patients treated with obeticholic acid or fibrates
Journal of Hepatology·2025
GS-009 Latest liver stiffness measurements predict liver-related outcomes in primary biliary cholangitis patients with discordant biochemical and liver stiffness responses
Journal of Hepatology·2025· 1 cited
Validation of PBC‐10 in Japanese patients with primary biliary cholangitis
Hepatology Research·2025· 1 citedOpen Access
Nationwide survey of patients with acute liver failure and late‐onset hepatic failure in Japan seen between 2016 and 2021
Hepatology Research·2025· 5 citedOpen Access
A placebo-controlled Phase 2 trial of E6011, anti-human fractalkine monoclonal antibody, in primary biliary cholangitis
Journal of Translational Autoimmunity·2025· 3 citedOpen Access
page 1 of 17Next →

Frequent Co-authors

Hajime Takikawa(17), M. Eric Gershwin(9), Masahiro Yoshida(8), Tadahiro Takada(7), Yoshifumi Kawarada(7), Yuji Nimura(7), Toshihiko Mayumi(7), Keita Wada(7), Fumihiko Miura(7), Masahiko Hirota(7), Toshio Tsuyuguchi(7), Hiromasa Ohira(7), Xiong Ma(7), Henry A. Pitt(6), Susumu Tazuma(6), Takahiro Nakazawa(5), Kazuichi Okazaki(5), Yuichi Yamashita(5), Masato Nagino(5), Steven M. Strasberg(5)